Last reviewed · How we verify
monoclonal antibody RAV12
At a glance
| Generic name | monoclonal antibody RAV12 |
|---|---|
| Sponsor | MacroGenics |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer (PHASE2)
- RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- monoclonal antibody RAV12 CI brief — competitive landscape report
- monoclonal antibody RAV12 updates RSS · CI watch RSS
- MacroGenics portfolio CI